查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1485955

全球登革热测试市场 - 全球产业分析、规模、占有率、成长、趋势、预测 (2031) - 依产品类型、依最终用户、依地区

Dengue Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 240 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球登革热盛行率正快速上升，对非洲、美洲、东地中海、东南亚和西太平洋等重点地区影响显着。世界卫生组织（WHO）报告登革热病例持续增加，凸显了对有效诊断解决方案的迫切需求。

美洲的登革热疫情已达到令人震惊的程度，报告了数百万例病例。巴西已成为热点地区，占这些案件的很大一部分。巴西登革热病例急剧上升凸显了健康危机的加深，与先前的数字相比大幅增加。

西太平洋地区也出现了大量疑似登革热病例。菲律宾和马来西亚是受影响最严重的国家，两国均报告病例数高。这些地区的登革热病毒疫情不断增加，对及时、准确检测至关重要的诊断试剂盒的需求增加。

气候变迁正在加剧世界各地的登革热流行。最近在以前未受影响的国家爆发的登革热、基孔肯雅热和西尼罗河病毒凸显了全球暖化的潜在威胁。气候变迁正在增加包括欧洲在内的各个地区当前和未来的风险，并对病媒分布和潜在的疾病传播产生重大影响。

本报告考察了全球登革热检测市场，并提供了市场概述，包括依产品类型、最终用户、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 经济概况
  • 杵分析

第 3 章 2018-2031 年全球登革热检测市场前景

  • 2018-2031 年全球登革热检测市场展望（依产品类型、价值（十亿美元））
  • 2018-2031 年全球登革热检测市场展望（依最终用户划分）价值（十亿美元）
  • 2018-2031 年全球登革热检测市场前景（依地区、价值（十亿美元））

第 4 章 2018-2031 年北美登革热检测市场前景

第 5 章欧洲登革热检测市场前景，2018-2031

第 6 章 2018-2031 年亚太地区登革热检测市场前景

第 7 章拉丁美洲登革热检测市场前景，2018-2031

第 8 章 2018-2031 年中东及非洲登革热检测市场前景

第九章竞争态势

  • 依产品和最终用户划分的热图
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Roche Molecular Systems Inc.
    • Abbott Laboratories
    • InBios International, Inc.
    • NovaTec Immundiagnostica GmbH
    • Quest Diagnostics
    • Certest Biotec S.L.
    • OriGene Technologies
    • Abnova Corporation
    • 其他

第 10 章附录

简介目录

The global incidence of dengue has been increasing rapidly, with significant impacts across major regions including Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. The World Health Organization (WHO) reports a continuous rise in dengue cases, highlighting the urgent need for effective diagnostic solutions.

Rising Dengue Cases Across the Globe

Americas

In the Americas, the prevalence of dengue has reached alarming levels, with millions of reported cases. Brazil has emerged as a hotspot, contributing a substantial portion of these cases. The surge in dengue cases in Brazil underscores the growing health crisis, with a significant increase compared to previous figures.

Western Pacific Region

The Western Pacific region has also witnessed a significant number of suspected dengue cases. The Philippines and Malaysia are among the most affected countries, both reporting high case numbers. This escalating prevalence of the dengue virus in these regions is driving the demand for diagnostic kits, crucial for timely and accurate detection.

Climate Change and Dengue Fever

Impact of Climate Change

Climate change is exacerbating the prevalence of dengue fever worldwide. Recent outbreaks of dengue, chikungunya, and West Nile virus in previously unaffected countries highlight the potential threats posed by global warming. Changes in climate have heightened current and future risks in various regions, including Europe, significantly impacting vector distribution and potential disease transmission.

Environmental Factors

Environmental factors such as high rainfall and humidity create favorable breeding conditions for mosquitoes. Additionally, curtailed water supply and disrupted sanitation services facilitate mosquito proliferation, while warm temperatures extend the active season for these vectors. These climatic changes are likely to increase the burden of dengue fever, subsequently driving the growth of the dengue testing market.

Innovations in Dengue Testing

Need for Cost-Effective Diagnostic Kits

Currently, the available diagnostic test kits for dengue are less effective, creating a need for cost-effective kits with high specificity and sensitivity. The high price and limited effectiveness of existing test kits have prompted companies to focus on developing reliable and affordable diagnostic methods. Increasing research and development activities aim to produce highly specific and sensitive diagnostic kits, opening new growth opportunities for manufacturers.

Development of Point-of-Care Tests

Manufacturers are prioritizing the development of point-of-care tests that are rapid, sensitive, and easy to use. Many existing methods for detecting the dengue virus rely on cell culture and mice inoculation, which are slow and expensive. There is a pressing need for rapid, user-friendly, and sensitive detection methods to enhance the efficiency of dengue diagnosis.

Global Dengue Testing Market by Region

Dominance of Asia Pacific

The Asia Pacific region has been at the forefront of the global dengue testing market in terms of revenue. This trend is expected to continue, with Asia Pacific projected to remain the most attractive market for dengue testing. The region's significant share in the global dengue testing market underscores its critical role in addressing the dengue epidemic.

Key Market Players Include:

  • Abnova Corporation
  • Roche Molecular Systems Inc.
  • Abbott Laboratories
  • InBios International, Inc.
  • NovaTec Immundiagnostica GmbH
  • Euroimmun AG (Sub. PerkinElmer)
  • Quest Diagnostics
  • Certest Biotec S.L.
  • OriGene Technologies
  • Thermo Fisher Scientific Inc.
  • Others.

Global Dengue Testing Market Segmentation:

By Product Type:

  • Premium
  • Mid
  • Low

By End User:

  • Hospitals
  • Public Health Laboratory
  • Diagnostic Centers
  • Others

By Region:

  • China
  • India
  • Japan
  • Indonesia
  • South Korea
  • Rest of Asia Pacific

Table of Contents

1. Executive Summary

  • 1.1. Global Dengue Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis

3. Global Dengue Testing Market Outlook, 2018 - 2031

  • 3.1. Global Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. ELISA-based Tests
      • 3.1.1.2. RT-PCR based Tests
      • 3.1.1.3. Dengue IgG/IgM Rapid Test
  • 3.2. Global Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospitals
      • 3.2.1.2. Public Health Laboratory
      • 3.2.1.3. Diagnostic Centers
      • 3.2.1.4. Others
  • 3.3. Global Dengue Testing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Dengue Testing Market Outlook, 2018 - 2031

  • 4.1. North America Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. ELISA-based Tests
      • 4.1.1.2. RT-PCR based Tests
      • 4.1.1.3. Dengue IgG/IgM Rapid Test
  • 4.2. North America Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospitals
      • 4.2.1.2. Public Health Laboratory
      • 4.2.1.3. Diagnostic Centers
      • 4.2.1.4. Others
  • 4.3. North America Dengue Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Dengue Testing Market Outlook, 2018 - 2031

  • 5.1. Europe Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. ELISA-based Tests
      • 5.1.1.2. RT-PCR based Tests
      • 5.1.1.3. Dengue IgG/IgM Rapid Test
  • 5.2. Europe Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospitals
      • 5.2.1.2. Public Health Laboratory
      • 5.2.1.3. Diagnostic Centers
      • 5.2.1.4. Others
  • 5.3. Europe Dengue Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Dengue Testing Market by Product Type, Value (US$Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Dengue Testing Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. ELISA-based Tests
      • 6.1.1.2. RT-PCR based Tests
      • 6.1.1.3. Dengue IgG/IgM Rapid Test
  • 6.2. Asia Pacific Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospitals
      • 6.2.1.2. Public Health Laboratory
      • 6.2.1.3. Diagnostic Centers
      • 6.2.1.4. Others
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Dengue Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Dengue Testing Market Outlook, 2018 - 2031

  • 7.1. Latin America Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. ELISA-based Tests
      • 7.1.1.2. RT-PCR based Tests
      • 7.1.1.3. Dengue IgG/IgM Rapid Test
  • 7.2. Latin America Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Hospitals
      • 7.2.1.2. Public Health Laboratory
      • 7.2.1.3. Diagnostic Centers
      • 7.2.1.4. Others
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Dengue Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Dengue Testing Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Dengue Testing Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. ELISA-based Tests
      • 8.1.1.2. RT-PCR based Tests
      • 8.1.1.3. Dengue IgG/IgM Rapid Test
  • 8.2. Middle East & Africa Dengue Testing Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Public Health Laboratory
      • 8.2.1.3. Diagnostic Centers
      • 8.2.1.4. Others
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Dengue Testing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Dengue Testing Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Dengue Testing Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Roche Molecular Systems Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Abbott Laboratories
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. InBios International, Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. NovaTec Immundiagnostica GmbH
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Quest Diagnostics
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Certest Biotec S.L.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. OriGene Technologies
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abnova Corporation
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Others
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1.Research Methodology
  • 10.2.Report Assumptions
  • 10.3.Acronyms and Abbreviations